biostudies-literatureWinzeler BSwiss National Science FoundationSwiss Academy of Medical SciencesG.& J. Bangerter-Rhyner Foundation, University Hospital and University of Basele151800https://www.ebi.ac.uk/biostudies/studies/S-EPMC8516458biostudies-literatureUnknown131(20)BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide 1 (GLP-1) reduces appetite and food intake. In experimental models, GLP-1 has also been shown to play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.MethodsIn this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other. During the last treatment week, patients attended an 8-hour evaluation visit with free access to waterThe Journal of clinical investigationA randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.PMC8516458162608-Sailer COChrist-Crain MCoynel DRefardt JVogt DRUrwyler SAZanchi DWinzeler BfalseA randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide 1 (GLP-1) reduces appetite and food intake. In experimental models, GLP-1 has also been shown to play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.MethodsIn this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other. During the last treatment week, patients attended an 8-hour evaluation visit with free access to water2021-01-01T00:00:00Z2021 Oct2026-05-08T22:37:43.104Z2022-02-11T16:20:03.204ZS-EPMC85164583447364510.1172/JCI15180010.1172/jci151800